Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.73 |
| ▸ | PRKCA | P17252 | 2/20 | 0.66 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.66 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.66 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.66 |
| ▸ | FAAH | O00519 | 2/20 | 0.62 |
| ▸ | SELP | P16109 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.59 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.59 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.59 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.59 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27968161 | 0.93 | LMNA (0.68) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL9394196 | 0.93 | LMNA (0.68) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL10477902 | 0.93 | LMNA (0.68) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| Xylitol SCHEMBL9745889 | 0.87 | PRKCA (0.67) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL3718763 | 0.86 | DGKA (0.62) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL1823472 | 0.86 | DGKA (0.62) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL1926653 | 0.85 | DGKA (0.61) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| Glycerin SCHEMBL8503063 | 0.85 | DGKA (0.68) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL11212203 | 0.85 | PRKCA (0.67) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL9808782 | 0.85 | PRKCA (0.67) | DGKAPRKCAPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280448-B1 | ABIRATERONE ACETATE LIPID FORMULATIONS | CAPSUGEL BELGIUM NV (BE) | 2020-12-30 | — | — | EP | claimed |
| US-10722527-B2 | Abiraterone acetate lipid formulations | CAPSUGEL BELGIUM NV (BE) | 2020-07-28 | — | — | US | claimed |
| US-20180125863-A1 | ABIRATERONE ACETATE LIPID FORMULATIONS | CAPSUGEL BELGIUM NV (BE) | 2018-05-10 | — | — | US | claimed |
| EP-3280448-A1 | ABIRATERONE ACETATE LIPID FORMULATIONS | Capsugel Belgium NV (BE) | 2018-02-14 | — | — | EP | claimed |
| WO-2016162229-A1 | ABIRATERONE ACETATE LIPID FORMULATIONS | CAPSUGEL BELGIUM N.V. (BE) | 2016-10-13 | — | — | WO | claimed |
| EP-3897593-A1 | CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS | Tilray, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3824908-A1 | ABIRATERONE ACETATE LIPID FORMULATIONS | Capsugel Belgium NV (BE) | 2021-05-26 | — | — | EP | disclosed |
| EP-3280448-B1 | ABIRATERONE ACETATE LIPID FORMULATIONS | CAPSUGEL BELGIUM NV (BE) | 2020-12-30 | — | — | EP | disclosed |
| US-20200316093-A1 | ABIRATERONE ACETATE LIPID FORMULATIONS | CAPSUGEL BELGIUM NV (BE) | 2020-10-08 | — | — | US | disclosed |
| US-10722527-B2 | Abiraterone acetate lipid formulations | CAPSUGEL BELGIUM NV (BE) | 2020-07-28 | — | — | US | disclosed |
| WO-2020150233-A1 | ORAL DISINTEGRATING FILMS FOR CANNABIS PRODUCTS | Tilray, Inc. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222362-A1 | ORAL DISINTEGRATING FILMS FOR CANNABIS PRODUCTS | Tilray, Inc. | 2020-07-16 | — | — | US | disclosed |
| WO-2020132181-A1 | CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS | Tilray, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200197358-A1 | CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS | Tilray, Inc. | 2020-06-25 | — | — | US | disclosed |
| US-20180125863-A1 | ABIRATERONE ACETATE LIPID FORMULATIONS | CAPSUGEL BELGIUM NV (BE) | 2018-05-10 | — | — | US | disclosed |
| EP-3280448-A1 | ABIRATERONE ACETATE LIPID FORMULATIONS | Capsugel Belgium NV (BE) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016162229-A1 | ABIRATERONE ACETATE LIPID FORMULATIONS | CAPSUGEL BELGIUM N.V. (BE) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016066611-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING CINACALCET AND METHODS FOR THEIR PREPARATION AND USE | CAPSUGEL BELGIUM N.V. (BE) | 2016-05-06 | — | — | WO | disclosed |
| US-6369501-B1 | Plasma display panel of minute cell structure with improved application of fluorescent material | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10722527-B2 | Abiraterone acetate lipid formulations | AR, CYP19A1, CYP46A1 | DGKA 274/4885PRKCA 1072/4885PRKCE 2411/4885 |
| US-20200316093-A1 | ABIRATERONE ACETATE LIPID FORMULATIONS | AR, CYP19A1, CYP46A1 | DGKA 274/4885PRKCA 1072/4885PRKCE 2411/4885 |
| US-20180125863-A1 | ABIRATERONE ACETATE LIPID FORMULATIONS | AR, CYP19A1, CYP46A1 | DGKA 274/4885PRKCA 1072/4885PRKCE 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.